{"id":37911,"date":"2025-11-05T18:18:50","date_gmt":"2025-11-05T11:18:50","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=37911"},"modified":"2025-11-05T18:18:50","modified_gmt":"2025-11-05T11:18:50","slug":"xtalpi-subsidiary-ailux-announces-strategic-collaboration-with-lilly-to-advance-bispecific-antibody-development","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=37911","title":{"rendered":"XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SHANGHAI<\/span><\/span>, Nov. 5, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (“Lilly”) to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.<\/p>\n

\n<\/div>\n

Through this collaboration, Lilly will gain access to Ailux’s AI-powered bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developability analytics to deliver therapeutic constructs with novel function, optimal efficacy and drug-like properties.<\/p>\n

Under the terms of the agreement, Lilly may nominate an undisclosed number of target pairs for bispecific antibody design and may also obtain a license to Ailux’s proprietary platform for internal use. The agreement includes upfront and near-term payments totaling a double-digit million-dollar amount, including a platform license option. The total potential value of the deal, which includes development, regulatory, and commercial milestone payments, is up to $345 million<\/span>.<\/p>\n

“Lilly has been a long-time partner of ours,” said Jian Ma<\/span>, PhD, CEO and co-founder of XtalPi. “We are proud to see Lilly expand this trusted relationship into the biologics space, recognizing the potential of our AI-enabled platforms to create transformative therapies.”<\/p>\n

“Bispecific antibodies represent one of the most promising directions in today’s therapeutic landscape,” said Alex (Yi) Li<\/span>, CEO of Ailux and SVP of XtalPi. “At Ailux, we have built AI-powered solutions that can rapidly engineer panels of monospecific antibodies into bispecifics with superior efficacy and developability. We are excited to collaborate with Lilly, a global leader in biotherapeutics, to advance next-generation molecules toward the clinic.”<\/p>\n

About Ailux<\/b><\/p>\n

Ailux is a biologics innovation company dedicated to developing advanced biotherapeutics with AI-powered solutions. As XtalPi’s dedicated biologics platform, Ailux integrates proprietary computational models with state-of-the-art wet lab capabilities to tackle previously undruggable targets and design molecules with novel therapeutic profiles. With a global team of more than 100 members, Ailux partners with leading biopharmaceutical companies to translate cutting-edge science into transformative medicines.<\/p>\n

About XtalPi<\/b><\/p>\n

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology<\/span> (MIT<\/span>). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SHANGHAI<\/span><\/span>, Nov. 5, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (“Lilly”) to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.<\/p>\n

\n<\/div>\n

Through this collaboration, Lilly will gain access to Ailux’s AI-powered bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developability analytics to deliver therapeutic constructs with novel function, optimal efficacy and drug-like properties.<\/p>\n

Under the terms of the agreement, Lilly may nominate an undisclosed number of target pairs for bispecific antibody design and may also obtain a license to Ailux’s proprietary platform for internal use. The agreement includes upfront and near-term payments totaling a double-digit million-dollar amount, including a platform license option. The total potential value of the deal, which includes development, regulatory, and commercial milestone payments, is up to $345 million<\/span>.<\/p>\n

“Lilly has been a long-time partner of ours,” said Jian Ma<\/span>, PhD, CEO and co-founder of XtalPi. “We are proud to see Lilly expand this trusted relationship into the biologics space, recognizing the potential of our AI-enabled platforms to create transformative therapies.”<\/p>\n

“Bispecific antibodies represent one of the most promising directions in today’s therapeutic landscape,” said Alex (Yi) Li<\/span>, CEO of Ailux and SVP of XtalPi. “At Ailux, we have built AI-powered solutions that can rapidly engineer panels of monospecific antibodies into bispecifics with superior efficacy and developability. We are excited to collaborate with Lilly, a global leader in biotherapeutics, to advance next-generation molecules toward the clinic.”<\/p>\n

About Ailux<\/b><\/p>\n

Ailux is a biologics innovation company dedicated to developing advanced biotherapeutics with AI-powered solutions. As XtalPi’s dedicated biologics platform, Ailux integrates proprietary computational models with state-of-the-art wet lab capabilities to tackle previously undruggable targets and design molecules with novel therapeutic profiles. With a global team of more than 100 members, Ailux partners with leading biopharmaceutical companies to translate cutting-edge science into transformative medicines.<\/p>\n

About XtalPi<\/b><\/p>\n

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology<\/span> (MIT<\/span>). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-37911","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37911"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37911\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}